1
|
Movahedi F, Hu RG, Becker DL, Xu C. Stimuli-responsive liposomes for the delivery of nucleic acid therapeutics. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2015; 11:1575-84. [PMID: 25819885 DOI: 10.1016/j.nano.2015.03.006] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/28/2014] [Revised: 02/07/2015] [Accepted: 03/11/2015] [Indexed: 10/23/2022]
Abstract
UNLABELLED Nucleic acid therapeutics (NATs) are valuable tools in the modulation of gene expression in a highly specific manner. So far, NATs have been actively pursued in both pre-clinical and clinical studies to treat diseases such as cancer, infectious and inflammatory diseases. However, the clinical application of NATs remains a considerable challenge owing to their limited cellular uptake, low biological stability, off-target effect, and unfavorable pharmacokinetics. One concept to address these issues is to deliver NATs within stimuli-responsive liposomes, which release their contents of NATs upon encountering environmental changes such as temperature, pH, and ion strength. In this case, before reaching the targeted tissue/organ, NATs are protected from degradation by enzymes and immune system. Once at the area of interest, localized and targeted delivery can be achieved with minimal influence to other parts of the body. Here, we discuss the latest developments and existing challenges in this field. FROM THE CLINICAL EDITOR Nucleic acid therapeutics have been shown to enhance or eliminate specific gene expression in experimental research. Unfortunately, clinical applications have so far not been realized due to problems of easy degradation and possible toxicity. The use of nanosized carriers such as liposomes to deliver nucleic acids is one solution to overcome these problems. In this review article the authors describe and discuss the potentials of various trigger-responsive "smart" liposomes, with a view to help other researchers to design better liposomal nucleic acid delivery systems.
Collapse
Affiliation(s)
- Fatemeh Movahedi
- School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore
| | - Rebecca G Hu
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
| | - David L Becker
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
| | - Chenjie Xu
- School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore.
| |
Collapse
|
2
|
Zelphati O, Szoka FC. Cationic Liposomes as an Oligonucleotide Carrier: Mechanism of Action. J Liposome Res 2008. [DOI: 10.3109/08982109709035480] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
3
|
Chen J, Irving A, McMillan N, Gu W. Future of RNAi-based therapies for human papillomavirus-associated cervical cancer. Future Virol 2007. [DOI: 10.2217/17460794.2.6.587] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Over 99% of cervical cancers are associated with infection of high-risk type human papillomaviruses (HPV). These viruses infect epithelial cells lining the cervix and express the early viral genes E6 and E7, which are oncogenes and are primarily responsible for the transformation of the epithelial cells. The continuous expression of those genes is essential for maintenance of the cancer cell phenotype and viability. These viral genes can be silenced using oligonucleotide-based techniques, for example RNAi, antisense RNA and ribozymes. In spite of promising results in vitro and in vivo, in mice, these methods have thus far proved unsuccessful in humans, owing to the lack of an effective delivery system amongst other limitations. In this review we will discuss potential gene-silencing strategies in cervical cancer that would target both viral genes such as E6 and E7, and cellular genes that become deregulated such as E2F, p53, Akt, mTor, NF-κB or Bcl-2. By investigating these approaches we may generate an effective treatment for HPV-induced cervical cancer using gene silencing.
Collapse
Affiliation(s)
- Jiezhong Chen
- University of Queensland, UQ Diamantina Institute, R-Wing, Princess Alexandra Hospital, Ipswich Rd, Brisbane, QLD 4102, Australia
| | - Aaron Irving
- University of Queensland, UQ Diamantina Institute, R-Wing, Princess Alexandra Hospital, Ipswich Rd, Brisbane, QLD 4102, Australia
| | - Nigel McMillan
- University of Queensland, UQ Diamantina Institute, R-Wing, Princess Alexandra Hospital, Ipswich Rd, Brisbane, QLD 4102, Australia
| | - Wenyi Gu
- University of Queensland, UQ Diamantina Institute, R-Wing, Princess Alexandra Hospital, Ipswich Rd, Brisbane, QLD 4102, Australia
| |
Collapse
|
4
|
Kari I, Syrjänen S, Johansson B, Peri P, He B, Roizman B, Hukkanen V. Antisense RNA directed to the human papillomavirus type 16 E7 mRNA from herpes simplex virus type 1 derived vectors is expressed in CaSki cells and downregulates E7 mRNA. Virol J 2007; 4:47. [PMID: 17547759 PMCID: PMC1892547 DOI: 10.1186/1743-422x-4-47] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2006] [Accepted: 06/04/2007] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Human papillomavirus (HPV) infection is known to be the most important etiologic factor of cervical cancer. There is no HPV specific therapy available for treatment of invasive squamous cell carcinoma of the cervix and its precursor lesions. The present study elucidates the potential to use herpes simplex virus (HSV) derived vectors for expression of antisense RNA to HPV -16 E7 oncogene. RESULTS We have constructed replication competent, nonneuroinvasive HSV-1 vectors, deleted of the gamma134.5 gene. The vectors express RNA antisense to the first 100 nucleotides of the HPV-16 E7 gene. We assayed the ability of the antisense E7 vectors R5225 (tk-) and R5226 (tk+), to produce antisense RNA, as well as the consequent effects on E7 mRNA and protein levels in HPV-16 positive CaSki cells. Anti-E7 RNA was expressed by both constructs in a dose-dependent manner. Expression of HPV-16 E7 mRNA was downregulated effectively in CaSki cells infected with the tk- recombinant R5225 or with R5226. The tk+ recombinant R5226 was effective in downregulating E7 protein expression. CONCLUSION We have shown that anti-E7 RNA expressed from an HSV vector could efficiently downregulate HPV-16 E7 mRNA and E7 protein expression in CaSki cells. We conclude that HSV vectors may become a useful tool for gene therapy of HPV infections.
Collapse
MESH Headings
- Antiviral Agents/pharmacology
- Cell Line, Tumor
- Down-Regulation
- Gene Expression/drug effects
- Gene Expression Regulation, Viral
- Genetic Vectors/genetics
- Herpesvirus 1, Human/genetics
- Human papillomavirus 16/genetics
- Humans
- Oncogene Proteins, Viral/biosynthesis
- Oncogene Proteins, Viral/genetics
- Papillomavirus E7 Proteins
- RNA, Antisense/biosynthesis
- RNA, Antisense/genetics
- RNA, Antisense/pharmacology
- RNA, Messenger/antagonists & inhibitors
- RNA, Messenger/biosynthesis
- RNA, Viral/antagonists & inhibitors
- RNA, Viral/biosynthesis
Collapse
Affiliation(s)
- Ilkka Kari
- Department of Virology, Institute of Dentistry, University of Turku, Turku, Finland
- MediCity Research Laboratory, Institute of Dentistry, University of Turku, Turku, Finland
- Department of Oral Pathology, Institute of Dentistry, University of Turku, Turku, Finland
| | - Stina Syrjänen
- MediCity Research Laboratory, Institute of Dentistry, University of Turku, Turku, Finland
- Department of Oral Pathology, Institute of Dentistry, University of Turku, Turku, Finland
| | - Bo Johansson
- MediCity Research Laboratory, Institute of Dentistry, University of Turku, Turku, Finland
- Department of Oral Pathology, Institute of Dentistry, University of Turku, Turku, Finland
- Department of Clinical Virology, Karolinska University Hospital, Stockholm, Sweden
| | - Piritta Peri
- Department of Virology, Institute of Dentistry, University of Turku, Turku, Finland
| | - Bin He
- The Marjorie B. Kovler Viral Oncology Laboratories, The University of Chicago, Chicago, IL, USA
- Department of Microbiology and Immunology, University of Illinois, Chicago, IL, USA
| | - Bernard Roizman
- The Marjorie B. Kovler Viral Oncology Laboratories, The University of Chicago, Chicago, IL, USA
| | - Veijo Hukkanen
- Department of Virology, Institute of Dentistry, University of Turku, Turku, Finland
- MediCity Research Laboratory, Institute of Dentistry, University of Turku, Turku, Finland
- Department of Microbiology, University of Oulu, Oulu, Finland
| |
Collapse
|
5
|
Bartsch M, Weeke-Klimp AH, Meijer DKF, Scherphof GL, Kamps JAAM. Cell-specific targeting of lipid-based carriers for ODN and DNA. J Liposome Res 2005; 15:59-92. [PMID: 16194928 DOI: 10.1081/lpr-64961] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
It is well recognized that there is an urgent need for non-toxic systemically applicable vectors for biologically active nucleotides to fully exploit the current potential of molecular medicine in gene therapy. Cell-specific targeting of non-viral lipid-based carriers for ODN and DNA is a prerequisite to attain the concentration of nucleic acids required for therapeutic efficacy in the target tissue. In this review we will address the most promising approaches to selective targeting of liposomal nucleic acid carriers in vivo. In addition, the routes of entry and intracellular processing of these carrier systems are discussed as well as physiological factors potentially interfering with the biological and/or therapeutic activity of their nucleotide pay-load.
Collapse
Affiliation(s)
- Martin Bartsch
- Department of Cell Biology, Section Liposome Research, Groningen University Institute for Drug Exploration (GUIDE), Groningen, The Netherlands
| | | | | | | | | |
Collapse
|
6
|
Abstract
Cyclodextrins (CyDs) have traditionally been used for dissolving hydrophobic chemicals into aqueous media, and more recently, for inducing cholesterol efflux from lipid-laden cells as a proposed mechanism for reversal of cardiovascular disease. This review discusses the potential of delivering therapeutic oligonucleotides to solid tumours using CyD molecules. The physicochemical properties of these oligosaccharide molecules, and the barriers posed by the solid tumour itself, factors that affect may affect the uptake of oligonucleotides by CyDs, are the major foci of this review.
Collapse
Affiliation(s)
- Crispin R Dass
- Genetic Technologies Pty. Ltd., Hanover St 3065 Fitzroy Australia.
| |
Collapse
|
7
|
Abstract
Oligonucleotides (ONs) are a new class of therapeutic compounds under investigation for the treatment of a variety of disease states, such as cancer and HIV, and for FDA approval of an anti-CMV retinitis antisense molecule (Vitravene trade mark, Isis Pharmaceuticals). However, these molecules are limited not only by poor cellular uptake, but also by a general lack of understanding regarding the mechanism(s) of ON cellular uptake. As a result, various delivery vehicles have been developed that circumvent the proposed mechanism of uptake, endocytosis, while improving target specific delivery and/or drug stability. This review describes various traditional and novel delivery mechanisms that have been employed to improve ON cellular delivery, cost effectiveness, and therapeutic efficacy.
Collapse
Affiliation(s)
- Melanie A Lysik
- Midwestern University, College of Pharmacy-Glendale, Department of Pharmaceutical Sciences, 19555 N 59th Avenue, Glendale, Arizona 18308, USA.
| | | |
Collapse
|
8
|
Abstract
The vasculature of a tumour provides the most effective route by which neoplastic cells may be reached and eradicated by drugs. The fact that a tumour's vasculature is relatively more permeable than healthy host tissue should enable selective delivery of drugs to tumour tissue. Such delivery is relevant to carrier-mediated delivery of genetic medicine to tumours. This review discusses the potential of delivering therapeutic oligonucleotides (ONs) to tumours using cationic liposomes and cyclodextrins (CyDs), and the major hindrances posed by the tumour itself on such delivery. Cationic liposomes are generally 100-200 nm in diameter, whereas CyDs typically span 1.5 nm across. Cationic liposomes have been used for the introduction of nucleic acids into mammalian cells for more than a decade. CyD molecules are routinely used as agents that engender cholesterol efflux from lipid-laden cells, thus having an efficacious potential in the management of atherosclerosis. A recent trend is to employ these oligosaccharide molecules for delivering nucleic acids in cells both in-vitro and in-vivo. Comparisons are made with other ON delivery agents, such as porphyrin derivatives (< 1 nm), branched chain dendrimers (approximately 10 nm), polyethylenimine polymers (approximately 10 nm), nanoparticles (20-1,000 nm) and microspheres (> 1 microm), in the context of delivery to solid tumours. A discourse on how the chemical and physical properties of these carriers may affect the uptake of ONs into cells, particularly in-vivo, forms a major basis of this review.
Collapse
Affiliation(s)
- Crispin R Dass
- Johnson & Johnson Research, Strawberry Hills, Australia.
| |
Collapse
|
9
|
Cao A, Briane D, Coudert R, Vassy J, Lievre N, Olsman E, Tamboise E, Salzmann JL, Rigaut JP, Taillandier E. Delivery and pathway in MCF7 cells of DNA vectorized by cationic liposomes derived from cholesterol. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT 2000; 10:369-80. [PMID: 11079576 DOI: 10.1089/oli.1.2000.10.369] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We have investigated the delivery and the pathway in tumoral MCF7 cells of DNA carried by liposomes prepared from (trimethyl aminoethane carbamoyl cholesterol iodide (TMAE-Chol), a cholesterol-based cationic lipid with a quaternary ammonium on the polar head. The structure of DNA-liposome complexes depends on the length of DNA and on the lipid-DNA charge ratio X. Spherical beads constitute fine structures of the observed complexes even when they appear as aggregates. For oligonucleotide transfer, dissociation from liposomes after transfection, penetration of the oligonucleotides into nuclei, and a long resident time were observed. For plasmid transfer, a correlation between the variation in the transfection level and the ultrastructure of complexes was demonstrated. The results showed a cellular route of lipid/plasmid complexes from the beginning by endocytosis, entrapped into endosomes, released by the latter until entry in the perinuclear area, and then penetration of plasmids inside the nuclei resulting in the observed expression of the beta-galactosidase gene.
Collapse
Affiliation(s)
- A Cao
- Laboratoire de Chimie Structurale et Spectroscopie Biomoléculaire, CNRS URA 1430, UFR de Médecine, Université Paris XIII, Bobigny, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Choo CK, Ling MT, Suen CK, Chan KW, Kwong YL. Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells. Gynecol Oncol 2000; 78:293-301. [PMID: 10985883 DOI: 10.1006/gyno.2000.5916] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
OBJECTIVE In cervical cancer, high-risk human papillomavirus (HPV) genes are expressed solely in cancerous cells and have been proposed to be the most important etiological factors for cervical cancer, thus making them suitable targets for gene therapy. In this study, we aim to inactivate the HPV16 E7 in CaSki cells and test the possibility of reducing the tumorigenicity of these cells. METHODS The full-length HPV16 E7 cDNA was cloned in the pBabe-puro or pWZL-Hygro retrovirus vector in reverse orientation and was stably transfected into CaSki cells by replication-defective retrovirus infection giving rise to CaSki-E7AS and CaSki-E7AS2X cells. Immunoprecipitation/Western analysis and real-time RT-PCR were performed to document the levels of HPV16 E7 gene product. Flow cytometry was performed to study changes in the cell cycle in response to reduced E7 protein. The expression of bcl-2, RB, and E2F-1 was studied using Western blot analysis. Tumorigenicity of CaSki, CaSki-E7AS, and CaSki-E7AS2X cells was assayed with subepidermal tumor growth in nude mice. RESULTS We have documented that the delivery of the antisense gene construct resulted in the reduction of HPV16 E7 protein expression and cell proliferation in CaSki cells. Furthermore, we demonstrated that these changes were accompanied by cell cycle arrest, up-regulation of RB, and down-regulation of E2F-1 and bcl-2 proteins. More importantly, dose-dependent transduction of the antisense HPV16E7 construct was able to inhibit and/or retard the tumorigenicity of CaSki cells in vivo. CONCLUSIONS Down-regulation of HPV16 E7 with antisense RNA is beneficial in reducing the tumorigenicity of CaSki cells and can potentially be useful for HPV-associated malignancy gene therapy.
Collapse
MESH Headings
- Animals
- Carrier Proteins
- Cell Cycle Proteins
- Cell Differentiation
- Cell Division
- DNA-Binding Proteins
- Down-Regulation
- E2F Transcription Factors
- E2F1 Transcription Factor
- Female
- Flow Cytometry
- Gene Expression Regulation, Neoplastic
- Gene Expression Regulation, Viral
- Gene Silencing
- Humans
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Neoplasm Transplantation
- Oncogene Proteins, Viral/antagonists & inhibitors
- Oncogene Proteins, Viral/biosynthesis
- Oncogene Proteins, Viral/genetics
- Papillomaviridae/genetics
- Papillomavirus E7 Proteins
- Proto-Oncogene Proteins c-bcl-2/biosynthesis
- Proto-Oncogene Proteins c-bcl-2/metabolism
- RNA, Antisense/administration & dosage
- RNA, Antisense/genetics
- Retinoblastoma Protein/biosynthesis
- Retinoblastoma Protein/metabolism
- Retinoblastoma-Binding Protein 1
- Retroviridae/genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Transcription Factor DP1
- Transcription Factors/biosynthesis
- Transcription Factors/metabolism
- Transfection
- Tumor Cells, Cultured
- Uterine Cervical Neoplasms/pathology
- Uterine Cervical Neoplasms/therapy
- Uterine Cervical Neoplasms/virology
Collapse
Affiliation(s)
- C K Choo
- Department of Medicine, Department of Pathology, Cancer Research Centre, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road, Hong Kong SAR, China.
| | | | | | | | | |
Collapse
|
11
|
Holmes AR, Dohrman AF, Ellison AR, Goncz KK, Gruenert DC. Intracellular compartmentalization of DNA fragments in cultured airway epithelial cells mediated by cationic lipids. Pharm Res 1999; 16:1020-5. [PMID: 10450925 DOI: 10.1023/a:1018927531003] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
PURPOSE The amount and intracellular distribution of DNA fragments (491-bp) was characterized after transfection in vitro with a commercially available cationic lipid. Localization of fragment to the nucleus, its subcellular distribution, and integrity within the cells was determined for various times after transfection. METHODS Cystic fibrosis (CF) airway epithelial cells were transfected with 32P and FITC labeled single-stranded (ss) or double-stranded (ds) DNA fragments complexed with Lipofectamine at various charge ratios. RESULTS A 511 (+/-) charge ratio was found to be the optimal ratio for transfection of both ss-and dsDNA. After a 5 h exposure, 7.51 +/- 0.89% of the radioactivity was associated with the nuclear fraction whereas only 1.07 +/- 0.23%, was found in the nuclear fraction when dsDNA was used. The nuclear radioactivity detected after a 24 h exposure was only 1/3 of that after 5 h. Analysis of fragment stability in the cytosolic and nuclear fractions showed the presence of intact fragment in each subcellular compartment. No intranuclear/intracellular fragment could be detected in control experiments with naked DNA. Conclusions. The results from these experiments indicate that small fragments of DNA can be efficiently and rapidly transferred intact to the cell nucleus using cationic lipids and that ssDNA fragments are more effective than dsDNA fragments for nuclear delivery.
Collapse
Affiliation(s)
- A R Holmes
- Gene Therapy Core Center, Cardiovascular Research Institute, University of California, San Francisco 94143, USA
| | | | | | | | | |
Collapse
|
12
|
Bagasra O, Amjad M, Mukhtar M. Liposomes in Gene Therapy. Gene Ther 1999. [DOI: 10.1007/978-3-0348-7011-5_5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Konopka K, Rossi JJ, Swiderski P, Slepushkin VA, Düzgüneş N. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. BIOCHIMICA ET BIOPHYSICA ACTA 1998; 1372:55-68. [PMID: 9651480 DOI: 10.1016/s0005-2736(98)00046-7] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Cationic liposome-mediated intracellular delivery of a fluorescein-labeled chimeric DNA-RNA ribozyme targeted to the HIV-1 5' LTR was investigated, using THP-1, THP-1/HIV-1IIIB or HeLa/LAV cells. Different fluorescence patterns were observed when the cells were exposed to Lipofectamine, Lipofectin or DMRIE:DOPE (1:1) complexed to the ribozyme. With Lipofectamine intense cell-associated fluorescence was found. Incubation with Lipofectin resulted in less intense diffuse fluorescence, while with DMRIE an intense but sporadic fluorescence was observed. Differentiated THP-1/HIV-1IIIB cells were more susceptible to killing by liposome-ribozyme complexes than THP-1 cells. Under non-cytotoxic conditions (a 4-h treatment) complexes of 5, 10 or 15 microM Lipofectin or DOTAP:DOPE (1:1) and ribozyme, at lipid:ribozyme ratios of 8:1 or 4:1, did not affect p24 production in THP-1/HIV-1IIIB cells in spite of the intracellular accumulation of the ribozyme. A 24-h exposure of THP-1/HIV-1IIIB cells to 5 microM Lipofectin or DOTAP:DOPE (1:1) complexed with either the functional or a modified control ribozyme reduced virus production by approximately 30%. Thus, the antiviral effect of the liposome-complexed ribozyme was not sequence-specific. In contrast, the free ribozyme at a relatively high concentration inhibited virus production by 30%, while the control ribozyme was ineffective, indicating a sequence-specific effect. Both Lipofectin and DOTAP complexed with ribozyme were toxic at 10 and 15 microM after a 24-h treatment. A 4-h treatment of HeLa/LAV cells with Lipofectin at 5, 10 or 15 microM was not toxic to the cells, but also did not inhibit p24 production. In contrast, treatment of HeLa CD4+ cells immediately after infection with HIV-1IIIB at the same lipid concentrations and lipid:ribozyme ratios was cytotoxic. Our results indicate that the delivery of functional ribozyme into cells by cationic liposomes is an inefficient process and needs extensive improvement before it can be used in ex vivo and in vivo applications.
Collapse
Affiliation(s)
- K Konopka
- Department of Microbiology, School of Dentistry, University of the Pacific, San Francisco, CA 94115, USA
| | | | | | | | | |
Collapse
|
14
|
Konopka K, Harrison GS, Felgner PL, Düzgüneş N. Cationic liposome-mediated expression of HIV-regulated luciferase and diphtheria toxin a genes in HeLa cells infected with or expressing HIV. BIOCHIMICA ET BIOPHYSICA ACTA 1997; 1356:185-97. [PMID: 9150276 DOI: 10.1016/s0167-4889(96)00176-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
HIV-regulated expression of the diphtheria toxin A fragment gene (HIV-DT-A) is a potential gene therapy approach to AIDS. Since cationic liposomes are safe and non-immunogenic for in vivo gene delivery, we examined whether LipofectAMINE or DMRIE reagent could mediate the transfection of HIV-DT-A (pTHA43) or the HIV-regulated luciferase gene (pLUCA43) into HIV-infected or uninfected HeLa cells. pLUCA43 was expressed at a 10(3)-fold higher level in HeLa/LAV cells than in uninfected HeLa cells, while the extent of expression of RSV-regulated luciferase was the same in both cell lines. Co-transfection of HeLa cells with pTHA43 and the proviral HIV clone, HXB deltaBgl, resulted in complete inhibition of virus production. In contrast, the delivery of HIV-DT-A to chronically infected HeLa/LAV or HeLa/IIIB cells, or to HeLa CD4+ cells before infection, did not have a specific effect on virus production, since treatment of cells with control plasmids also reduced virus production. This reduction could be ascribed to cytotoxicity of the reagents. The efficiency of transfection, as measured by the percentage of cells expressing beta-gal, was approximately 5%. Thus, cationic liposome-mediated transfection was too inefficient to inhibit virus production when the DT-A was delivered by cationic liposomes to chronically- or de novo- infected cells. However, when both the virus and DT-A genes were delivered into the same cells by cationic liposomes, DT-A was very effective at inhibiting virus production. Our results indicate that the successful use of cationic liposomes for gene therapy will require the improvement of their transfection efficiency.
Collapse
Affiliation(s)
- K Konopka
- Department of Microbiology, School of Dentistry, University of the Pacific, San Francisco, CA 94115, USA
| | | | | | | |
Collapse
|
15
|
Vlassov VV, Vlassova IE, Pautova LV. Oligonucleotides and polynucleotides as biologically active compounds. PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY 1997; 57:95-143. [PMID: 9175432 DOI: 10.1016/s0079-6603(08)60279-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- V V Vlassov
- Institute of Bioorganic Chemistry, Novosibirsk, Russia
| | | | | |
Collapse
|
16
|
Ollikainen H, Lappalainen K, Jääskeläinen I, Syrjänen S, Pulkki K. Liposomal targeting of bcl-2 antisense oligonucleotides with enhanced stability into human myeloma cell lines. Leuk Lymphoma 1996; 24:165-74. [PMID: 9049973 DOI: 10.3109/10428199609045725] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Cationic liposomes improve the delivery of antisense oligonucleotides (ODNs) into cells. However, there is marked variability in the cellular uptake of ODNs into different cell lines. We used liposomes containing dimethyloctadecylammonium bromide (DDAB) and dioleoylphosphatidylethanolamine (DOPE) to increase the delivery of phosphodiester ODNs into four different myeloma cell lines. The delivery by cationic liposomes increased the delivery of bcl-2 antisense ODNs by a factor of 9 to 45 as compared to plain ODNs. The stability of ODNs was increased with liposomes both in the culture medium and within the cells. Intact liposomal ODNs were detected inside the cells up to 24 hours with gel electrophoresis and phosphor imager analysis. Antisense ODNs had no effect on bcl-2 mRNA levels. Also the proliferation of myeloma cells remained unchanged during the 3-day incubation period. Our study shows that liposomal antisense ODNs targeting bcl-2 of human myeloma cells result in increased stability of ODNs with minimal toxicity. However, further modifications are needed to gain biological effects of antisense ODNs on human myeloma cells.
Collapse
Affiliation(s)
- H Ollikainen
- MediCity Research Laboratory, University of Turku, Finland
| | | | | | | | | |
Collapse
|
17
|
Zelphati O, Szoka FC. Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet? J Control Release 1996. [DOI: 10.1016/0168-3659(96)01361-2] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
18
|
Konopka K, Pretzer E, Felgner PL, Düzgüneş N. Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. BIOCHIMICA ET BIOPHYSICA ACTA 1996; 1312:186-96. [PMID: 8703987 DOI: 10.1016/0167-4889(96)00033-x] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Cationic liposomes may be valuable for the delivery of anti-sense oligonucleotides, ribozymes, and therapeutic genes into human immunodeficiency virus type 1 (HIV-1)-infected and uninfected cells. We evaluated the toxicity of three cationic liposomal preparations, Lipofectamine, Lipofectin, and 1, 2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DMRIE) reagent, to HIV-infected and uninfected cells. Monocyte/macrophages were infected with HIV-1BaL and treated with liposomes in medium containing 20% fetal bovine serum (FBS) for 4 h or 24 h at 37 degree C. Uninfected monocytic THP-1 cells and chronically infected THP-1/HIV-1IIIB cells were treated with phorbol 12-myristate 13-acetate (PMA) and exposed to liposomes in the presence of 10% FBS. Toxicity was evaluated by the Alamar Blue assay and viral p24 production. The toxic effect of cationic liposomes was very limited with uninfected cells, although concentrations of liposomes that were not toxic within a few days of treatment could cause toxicity at later times. In HIV-1BaL-infected macrophages, Lipofectamine (up to 8 microM) and Lipofectin (up to 40 microM) were not toxic after a 4-h treatment, while DMRIE reagent at 40 microM was toxic. While a 4-h treatment of THP-1/HIV-1IIIB cells with the cationic liposomes was not toxic, even up to 14 days post-treatment, all three cationic liposomes were toxic to cells at the highest concentration tested after a 24-h treatment. Similar results were obtained with the Alamar Blue assay, Trypan Blue exclusion and a method that enumerates nuclei. Infected cells with relatively high overall viability could be impaired in their ability to produce virions, indicating that virus production appears to be more sensitive to treatment with the cationic liposomes than cell viability. Our results indicate that HIV-infected cells are more susceptible than uninfected cells to killing by cationic liposomes. The molecular basis of this differential effect is unknown; it is proposed that alterations in cellular membranes during virus budding cause enhanced interactions between cationic liposomes and cellular membranes.
Collapse
Affiliation(s)
- K Konopka
- Department of Microbiology, University of the Pacific School of Dentistry, San Francisco, CA 94115, USA
| | | | | | | |
Collapse
|
19
|
Abstract
Liposomal drug-delivery systems have come of age in recent years, with several liposomal drugs currently in advanced clinical trials or already on the market. It is clear from numerous pre-clinical and clinical studies that drugs, such as antitumor drugs, packaged in liposomes exhibit reduced toxicities, while retaining, or gaining enhanced, efficacy. This results, in part, from altered pharmacokinetics, which lead to drug accumulation at disease sites, such as tumors, and reduced distribution to sensitive tissues. Fusogenic liposomal systems that are under development have the potential to deliver drugs intracellularly, and this is expected to markedly enhance therapeutic activity. Advances in liposome design are leading to new applications for the delivery of new biotechnology products, such as recombinant proteins, antisense oligonucleotides and cloned genes.
Collapse
Affiliation(s)
- A Chonn
- INEX Pharmaceuticals Corporation, Vancouver, Canada
| | | |
Collapse
|
20
|
Lappalainen K, Jääskeläinen I, Syrjänen K, Urtti A, Syrjänen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res 1994; 11:1127-31. [PMID: 7971713 DOI: 10.1023/a:1018932714745] [Citation(s) in RCA: 167] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The present study compares different cytotoxicity and cell proliferation assays including cell morphology, mitochondrial activity, DNA synthesis, and cell viability and toxicity assays. CaSki cells were exposed to two cationic liposomal preparations containing dimethyldioctadecyl-ammonium bromide (DDAB), dioleoylphosphatidylethanolamine (DOPE) and a commercial transfection-reagent DOTAP (N[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium-methylsulfat e). The results provided by these assays were similar. However, the lactate dehydrogenase assay was more sensitive in measuring early damages of cell membranes than the Trypan blue assay. Also, cell morphology showed early toxic changes, such as cytoplasmic vacuolization and cell shrinking, and it should be included with such toxicity evaluations. DDAB:DOPE was more toxic than DOTAP. The cells treated with DOTAP at 10 microM were surviving as well as the control cells, while DOTAP at 40 uM and DDAB:DOPE at 10 microM had slight toxic effects on CaSki cells. The most toxic effects were seen in CaSki cells after treatment with DDAB:DOPE at 40 microM.
Collapse
Affiliation(s)
- K Lappalainen
- MediCity Research Laboratory, Faculty of Medicine, University of Turku, Finland
| | | | | | | | | |
Collapse
|